Inspiration Healthcare gets CE-mark for new cerebral function monitor
Inspiration Healthcare Group
15.81p
14:00 15/11/24
Medical device company Inspiration Healthcare Group announced on Thursday that its new-generation cerebral function monitor (CFM) unit, the Unique+, designed for use in neonatal applications has been granted a CE mark.
Chemicals
7,290.96
15:45 15/11/24
FTSE AIM All-Share
728.67
15:45 15/11/24
The AIM-traded firm said the product would be released for sale in the UK starting in February, followed “swiftly” by major European markets and other key territories in the world as the product becomes registered with the respective regulatory bodies.
It said the CFM unit was designed to monitor the electrical activity in the brain of neonatal infants and had been a key component of Inspiration Healthcare's product offering since 2004.
The new Unique+ was the next generation of CFM offered by Inspiration with the further refinement of both hardware and software elements, and the addition of smart features to improve connectivity and the user experience.
Those new features included a combined amplifier and headbox in one battery powered, lightweight unit and modern user interface, and the simple identification of electrode placement with LED-lit connection points for single channel and dual channel monitoring.
It also included connectivity via USB, Bluetooth and the additional option of WiFi, enabling remote connectivity to PCs or hospital computer networks.
Inspiration described Unique+ as “state-of-the-art”, adding that it could be introduced into previously untapped markets including North America and Russia.
At the same time, Inspiration announced that it has renewed a distribution contract with Neotech Products - the US specialist manufacture of products used in neonatal intensive care applications - agreeing a further two-year term.
In the current year, the company estimated the total revenues from the sale of Neotech products in the UK would amount to more than £0.1m.
“The Unique+ CFM re-affirms Inspiration Healthcare's commitment to improving diagnostic and treatment of the newborn brain,” said CEO Neil Campbell.
“It also shows our commitment to investing in new technology and developing our product portfolio that will allow us to penetrate further into key international markets.
“We are also delighted to extend our relationship with Neotech and continuing as the UK distributors for their medical devices.”